Saluda Medical agreed a four-year loan with Medtronic to develop its Evoke evoked action compound potential-controlled, Closed-Loop Spinal Cord Stimulation System for the treatment of chronic intractable pain of the trunk and limbs.
1. The ECAP-controlled SCS system is Saluda's debut device, which measures the spinal cord's response to stimulation.
2. The device adjusts on every pulse to maximize activation within the patient's therapeutic window and seeks to maintain long-term results through ECAP control.
3. Medtronic is an existing shareholder of Saluda Medical after participating in two prior financing rounds. Further terms of the loan were not disclosed.
"This funding provides us with the financial flexibility to accelerate further development of our novel closed-loop SCS system and prepare for commercialization," said John Parker, CEO of Saluda Medical. "We are passionate about bringing ECAP-controlled, closed-loop technology to the field of pain management to develop mechanistic-based therapies for patients."